---
title: "Catalyst Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors"
description: "Catalyst Pharmaceuticals Inc. (CPRX) shares fell 7.23% to $23.08 on Friday, ending a three-day winning streak amid a broader market decline, with the NASDAQ down 0.92% and the Dow Jones down 1.05%. Th"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277256741.md"
published_at: "2026-02-27T22:23:04.000Z"
---

# Catalyst Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

> Catalyst Pharmaceuticals Inc. (CPRX) shares fell 7.23% to $23.08 on Friday, ending a three-day winning streak amid a broader market decline, with the NASDAQ down 0.92% and the Dow Jones down 1.05%. The stock is now 13.17% below its 52-week high of $26.58. In contrast, competitors like Johnson & Johnson, Pfizer, and Abbott Laboratories saw gains. Trading volume reached 1.7 million, surpassing the 50-day average of 1.2 million.

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Catalyst Pharmaceuticals Inc. (CPRX) slid 7.23% to $23.08 Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index falling 0.92% to 22,668.21 and Dow Jones Industrial Average falling 1.05% to 48,977.92.

The stock's fall snapped a three-day winning streak.

Catalyst Pharmaceuticals Inc. closed 13.17% below its 52-week high of $26.58, which the company achieved on June 9th.

The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) rose 2.04% to $248.43, Pfizer Inc. (PFE) rose 2.03% to $27.65, and Abbott Laboratories (ABT) rose 0.08% to $116.35.

Trading volume (1.7 M) eclipsed its 50-day average volume of 1.2 M.

Data source: Dow Jones Market Data, FactSet. Data compiled February 27, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

02-27-26 1723ET

### Related Stocks

- [CPRX.US - Catalyst Pharma](https://longbridge.com/en/quote/CPRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Insights into Catalyst Pharmaceuticals Q4 Earnings | Catalyst Pharmaceuticals (NASDAQ:CPRX) reported Q4 earnings on February 25, 2026, beating estimates by 38.78% with an EP | [Link](https://longbridge.com/en/news/276939197.md) |
| Catalyst Pharmaceuticals 2025 revenue beats estimates | Catalyst Pharmaceuticals reported a 19.8% year-over-year revenue growth for 2025, surpassing analyst expectations. Q4 re | [Link](https://longbridge.com/en/news/276940426.md) |
| Navigating the new 15% global tariff: What it means for US consumers | A new 15% global tariff will be implemented on February 24, 2026, as introduced by President Donald Trump. This policy w | [Link](https://longbridge.com/en/news/277086558.md) |
| IMF’s Georgieva says tariffs lifted US goods inflation, backs Fed rate at 3.25%–3.5% | IMF Managing Director Kristalina Georgieva stated that US goods inflation has been influenced by tariffs, even as overal | [Link](https://longbridge.com/en/news/276951006.md) |
| Tariff rate for some nations will rise to 15 percent: Trade representative | U.S. Trade Representative Jamieson Greer announced that some nations will see tariffs rise to 15 percent or higher as pa | [Link](https://longbridge.com/en/news/276951793.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.